IP Library Granted Patent US 8,172,770
Granted Patent B2
US 8,172,770 · App. 11/550,209 · Granted May 8, 2012

System and method for minimally invasive disease therapy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,172,770
App. No.
11/550,209
Granted
May 8, 2012
Kind
B2
Abstract

A system for treating a lesion site of a patient is disclosed. The system includes a cannula having a lumen, a conduit in communication with said lumen, an introducer stylet removably disposed within said cannula, a resecting device selectively insertable within said cannula, and an adjuvant treatment device selectively insertable within said cannula.

Claims (35)

1. A method of establishing a margin region comprising:

forming a cavity by resecting tissue, said cavity having an inner wall of tissue at a desired biopsy location;

applying ink to at least a portion of said inner wall of said cavity subsequent to forming said cavity, said ink penetrating said tissue to form an inked tissue region at least partially defined by said inner wall and an inked tissue boundary located a distance from said inner wall, said inked tissue boundary separating said inked tissue from non-inked tissue;

removing a tissue sample comprising at least a portion of said inked tissue boundary, and at least a portion of said inked and non-inked tissue; and

determining a pathology of said inked portion of said tissue sample.

2. The method of claim 1 , wherein said determining a pathology comprises testing said inked tissue for cancerous material.

3. The method of claim 1 , further comprising:

repeating applying ink to at least a portion of said inner wall of said cavity to form an inked tissue region having an inked tissue boundary, removing a tissue sample comprising at least a portion of said inked tissue boundary, and determining a pathology of an inked portion of said tissue sample, when the pathology of a previous tissue sample indicates diseased tissue is present within said inked portion of said previous tissue sample.

4. The method of claim 1 , wherein said determining a pathology comprises determining whether said inked portion of said tissue sample is clear of diseased material.

5. The method of claim 1 , further comprising:

administering an adjuvant treatment.

6. The method of claim 5 , wherein said adjuvant treatment is selected from one of: resecting tissue, ablating tissue, heating tissue, freezing tissue, applying chemicals to tissue, external beam HIFU therapy, interstitial HIFU therapy, electroporation therapy, ultrasonicporation therapy, interstitial microwave therapy, and brachytherapy.

7. The method of claim 5 , further comprising:

inserting an adjuvant therapy device into said cavity; and

applying a vacuum within said cavity while administering said adjuvant treatment, said vacuum causing said cavity to collapse around said adjuvant treatment device.

8. The method of claim 5 , further comprising administering a haemostatic agent to said inner wall prior to administering said adjuvant treatment.

9. The method of claim 5 , further comprising administering said adjuvant treatment before applying said ink to said inner wall.

10. The method of claim 5 , further comprising administering said adjuvant treatment to said inner wall of said cavity before applying said ink to said inner wall.

11. The method of claim 1 , further comprising:

administering a haemostatic agent to said cavity before applying said ink to said inner wall.

12. The method of claim 11 , further comprising administering an adjuvant treatment to said inner wall of said cavity after administering said haemostatic agent to said cavity and before applying said ink to said inner wall.

13. The method of claim 1 , further comprising locating an inked portion of said tissue sample determined to have been located nearest to said cavity for testing.

14. The method of claim 13 , wherein determining a pathology comprises testing said portion of said inked tissue sample determined to have been located nearest to said cavity.

15. The method of claim 1 , further comprising removing a second tissue sample and determining the presence of inked tissue in said second tissue sample, and repeating said step of removing said tissue sample when the second tissue sample is determined to have inked tissue.

16. A treatment method for improving an adjuvant therapy comprising:

resecting tissue to form a cavity having surrounding tissue and an inner wall;

applying a haemostatic agent to said surrounding tissue;

applying an adjuvant therapy by an adjuvant therapy device to said surrounding tissue following application of said haemostatic agent;

applying ink to at least a portion of said inner wall of said cavity following application of said adjuvant therapy, said ink penetrating said tissue to create an inked tissue region at least partially defined by said inner wall and an inked tissue boundary located a distance from said inner wall, said inked tissue boundary separating said inked tissue from non-inked tissue;

resecting a tissue sample from said surrounding tissue after said applying said adjuvant therapy, said tissue sample including at least a portion of said inked tissue boundary, and at least a portion of said inked and non-inked tissue; and

determining whether said inked portion of said tissue sample is clear of diseased material.

17. The method of claim 16 , further comprising:

continuing to resect tissue to form a larger cavity if said inked tissue is determined as not clear of diseased material.

18. The method of claim 17 , further comprising repeating applying said haemostatic agent, applying said adjuvant therapy, applying said ink to said inner wall, and resecting a tissue sample, when said determining a pathology indicates cancerous material is present within said inked portion of said tissue sample.

19. The method of claim 16 , wherein the adjuvant therapy is selected from one of: resecting tissue, ablating tissue, heating tissue, freezing tissue, applying chemicals to tissue, external beam HIFU therapy, interstitial HIFU therapy, electroporation therapy, ultrasonicporation therapy, interstitial microwave therapy, and brachytherapy.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →